Lucentis (Ranibizumab) is a monoclonal antibody, a class of medications called vascular endothelial growth factor A (VEGF-A) antagonist that works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels used to treat the wet form of age-related macular degeneration.
A humanized monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA technology, Ranibizumab is indicated in adults for:
The treatment of neovascular (wet) age-related macular degeneration (AMD-an an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities).
The treatment of visual impairment due to macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss), diabetic macular edema (DME- an eye disease caused by diabetes that can lead to vision loss)
The treatment of proliferative diabetic retinopathy (PDR- damage to the eyes caused by diabetes)
The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
The treatment of visual impairment due to choroidal neovascularisation (CNV)
Lucentis is indicated in preterm infants for:
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.